This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Merryman RW , Redd RA , Nishihori T , Chavez J , Nieto Y , Darrah JM , Rao U , Byrne MT , Bond DA , Maddocks KJ , Spinner MA , Advani RH , Ballard HJ , Svoboda J , Singh AK , McGuirk JP , Modi D , Ramchandren R , Romancik J , Cohen JB , Frigault MJ , Chen YB , Serritella AV , Kline J , Ansell S , Nathan S , Rahimian M , Joyce RM , Shah M , David KA , Park S , Beaven AW , Habib A , Bachanova V , Nakhoda S , Khan N , Lynch RC , Smith SD , Ho VT , LaCasce A , Armand P , Herrera AF
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Blood Adv. 2021 Mar 23;5(6) :1648-1659
PMID: 33710337 PMCID: PMC7993097 URL: https://www.ncbi.nlm.nih.gov/pubmed/33710337
AbstractAutologous stem cell transplantation (ASCT) can be curative for patients with relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 monoclonal antibodies (mAbs) can sensitize patients to subsequent chemotherapy, we hypothesized that anti-PD-1 therapy before ASCT would result in acceptable outcomes among high-risk patients who progressed on or responded insufficiently to ≥1 salvage regimen, including chemorefractory patients who are traditionally considered poor ASCT candidates. We retrospectively identified 78 HL patients who underwent ASCT after receiving an anti-PD-1 mAb (alone or in combination) as third-line or later therapy across 22 centers. Chemorefractory disease was common, including 42 patients (54%) refractory to ≥2 consecutive systemic therapies immediately before anti-PD-1 treatment. Fifty-eight (74%) patients underwent ASCT after anti-PD-1 treatment, while 20 patients (26%) received additional therapy after PD-1 blockade and before ASCT. Patients received a median of 4 systemic therapies (range, 3-7) before ASCT, and 31 patients (41%) had a positive pre-ASCT positron emission tomography (PET) result. After a median post-ASCT follow-up of 19.6 months, the 18-month progression-free survival (PFS) and overall survival were 81% (95% CI, 69-89) and 96% (95% confidence interval [CI], 87-99), respectively. Favorable outcomes were observed for patients who were refractory to 2 consecutive therapies immediately before PD-1 blockade (18-month PFS, 78%), had a positive pre-ASCT PET (18-month PFS, 75%), or received ≥4 systemic therapies before ASCT (18-month PFS, 73%), while PD-1 nonresponders had inferior outcomes (18-month PFS, 51%). In this high-risk cohort, ASCT after anti-PD-1 therapy was associated with excellent outcomes, even among heavily pretreated, previously chemorefractory patients.
Notes2473-9537 Merryman, Reid W Redd, Robert A Nishihori, Taiga Chavez, Julio Nieto, Yago Darrah, Justin M Rao, Uttam Byrne, Michael T Bond, David A Maddocks, Kami J Spinner, Michael A Advani, Ranjana H Ballard, Hatcher J Svoboda, Jakub Singh, Anurag K McGuirk, Joseph P Modi, Dipenkumar Ramchandren, Radhakrishnan Romancik, Jason Cohen, Jonathon B Frigault, Matthew J Chen, Yi-Bin Serritella, Anthony V Kline, Justine Ansell, Stephen Nathan, Sunita Rahimian, Maryam Joyce, Robin M Shah, Mansi David, Kevin A Park, Steven Beaven, Anne W Habib, Alma Bachanova, Veronika Nakhoda, Shazia Khan, Nadia Lynch, Ryan C Smith, Stephen D Ho, Vincent T LaCasce, Ann Armand, Philippe Herrera, Alex F Journal Article Blood Adv. 2021 Mar 23;5(6):1648-1659. doi: 10.1182/bloodadvances.2020003556.